These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32724113)

  • 1. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
    Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
    Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.
    Chang YH; Wu KC; Wang KH; Ding DC
    Cell Transplant; 2024; 33():9636897241281869. PubMed ID: 39323050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
    Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
    Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.
    Ito Y; Kondo J; Masuda M; Matsuzaki S; Onuma K; Kanda M; Watanabe Y; Sakaguchi H; Yoshino K; Ueda Y; Kamiura S; Kimura T; Inoue M
    Hum Cell; 2023 Mar; 36(2):752-761. PubMed ID: 36474106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
    Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
    Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro drug testing using patient-derived ovarian cancer organoids.
    Chen LY; Chou YT; Liew PL; Chu LH; Wen KC; Lin SF; Weng YC; Wang HC; Su PH; Lai HC
    J Ovarian Res; 2024 Oct; 17(1):194. PubMed ID: 39358778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
    Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
    Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
    Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
    Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
    Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
    Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Patient-Derived Ovarian Cancer Models.
    Maru Y; Hippo Y
    Cells; 2019 May; 8(5):. PubMed ID: 31130643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
    Seol HS; Oh JH; Choi E; Kim S; Kim H; Nam EJ
    J Gynecol Oncol; 2023 May; 34(3):e35. PubMed ID: 36659831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.